SCHEMBL2168244

SCHEMBL2168244

O=Cc1ccc(OCc2ccccc2F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.60
PKM P14618 1/20 0.60
MAOB P27338 6/20 0.59
PARP15 Q460N3 2/20 0.59
PARP10 Q53GL7 2/20 0.59
PARP14 Q460N5 1/20 0.59
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
SCN3A Q9NY46 1/20 0.53
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
TP53 P04637 1/20 0.48
ALOX12 P18054 1/20 0.48
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556124 0.86 PTPN1 (0.56) TSHRPKMMAOBPARP15PARP10
SCHEMBL4244280 0.86 PTPN1 (0.56) TSHRPKMMAOBPARP15PARP10
SCHEMBL2668344 0.85 NPC1 (0.51) TSHRPKMMAOBPARP15PARP10
SCHEMBL8639387 0.84 ALDH1A1 (0.50) TSHRPKMMAOBPARP15PARP10
SCHEMBL4200604 0.83 NPC1 (0.68) TSHRMAOBPARP15PARP10KDM4E
SCHEMBL29476007 0.82 PDCD1 (0.47) TSHRPKMMAOBPARP15PARP10
SCHEMBL712032 0.81 MAOB (0.50) TSHRMAOBPARP15PARP10PARP14
SCHEMBL6685478 0.81 ALDH1A1 (0.51) TSHRPKMMAOBKDM4EALDH1A1
SCHEMBL19595052 0.81 MAOB (0.56) TSHRMAOBPARP15PARP10PARP14
SCHEMBL30768078 0.81 MAOB (0.53) TSHRPKMMAOBPARP15PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104523668-B High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof 纽朗制药有限公司 2020-06-09 CN claimed
EP-2229351-B1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE NEWRON PHARM SPA (IT) 2017-11-08 EP claimed
EP-2029524-B1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES NEWRON PHARM SPA (IT) 2014-11-26 EP claimed
US-8846763-B2 High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof NEWRON PHARMACEUTICALS, S.P.A. (IT) 2014-09-30 US claimed
US-20140051758-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF NEWRON PHARMACEUTICALS S.P.A. (IT) 2014-02-20 US claimed
US-8530701-B2 High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof NEWRON PHARMACEUTICALS, S.P.A. (IT) 2013-09-10 US claimed
US-8278485-B2 Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides NEWRON PHARMACEUTICALS S.P.A. (IT) 2012-10-02 US claimed
EP-2474521-A1 High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them Newron Pharmaceuticals S.p.A. (IT) 2012-07-11 EP claimed
US-20120157712-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2012-06-21 US claimed
US-8076515-B2 Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides NEWRON PHARMACEUTICALS S.P.A. (IT) 2011-12-13 US claimed
US-20100324141-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-12-23 US claimed
EP-2229351-A1 PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE Newron Pharmaceuticals S.p.A. (IT) 2010-09-22 EP claimed
WO-2009074478-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-06-18 WO claimed
US-20090156678-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-06-18 US claimed
EP-2029524-A1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES Newron Pharmaceuticals S.p.A. (IT) 2009-03-04 EP claimed
WO-2007147491-A1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-12-27 WO claimed
EP-4611747-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS Genep Inc. (US) 2025-09-10 EP disclosed
WO-2024097171-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS GENEP INC. (US) 2024-05-10 WO disclosed
EP-0986540-A1 CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF Cocensys, Inc. (US) 2000-03-22 EP disclosed
WO-1998047869-A1 CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF COCENSYS, INC. (US) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156678-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES PTMA, PSMB2, PDGFRA TSHR 2646/4885PKM 858/4885MAOB 129/4885
US-20140051758-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF KCNH3, KCNB2, KCNH2 TSHR 2376/4885PKM 488/4885MAOB 149/4885
US-20100324141-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF PDE7A, PDE8B, PDE9A TSHR 2195/4885PKM 1182/4885MAOB 53/4885
US-20120157712-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES PTMA, PSMB2, PDGFRA TSHR 2646/4885PKM 858/4885MAOB 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.